Columbia University Medical Center (CUMC) researchers have created a computational tool that can rapidly predict which genes are implicated in an individual’s cancer and recommend treatments. It is among the most comprehensive tools of its kind, and the first that incorporates a user-friendly web interface that requires little knowledge of bioinformatics.
Researchers at University of Vienna discover unexpected role of signalling protein in hepatocellular carcinoma.
A team of UCLA bioengineers has demonstrated that its technology may go a long way toward overcoming the challenges of treatment for acute lymphoblastic leukemia, among the most common types of cancer in children, and has the potential to help doctors personalize drug doses.
University of Adelaide researchers have developed an optical fiber probe that distinguishes breast cancer tissue from normal tissue – potentially allowing surgeons to be much more precise when removing breast cancer.
When Kerstin Stenson, MD, describes the innovative technique she is helping develop to fight cancer, it seems like she’s describing a Tom Clancy military espionage novel.
Physicians have long used visual judgment of medical images to determine the course of cancer treatment. A new program package from Fraunhofer researchers reveals changes in images and facilitates this task using deep learning. The experts will demonstrate this software in Chicago from November 27 to December 2 at RSNA, the world’s largest radiology meeting.
At the MEDICA 2016 IMMS is presenting its first approaches for the personalized diagnostics of cancer using a prototype device. It was developed in the three-year research project INSPECT which started in June 2016.
Brain cancer treatment is taking a major step ahead as Spanish surgeons pioneer a new technique that spares language and motion functions. This splendid development might even one day result in epilepsy surgery.
Scientists have shown that a mutation in a gene called Arid1b can cause liver cancer. The gene normally protects against cancer by limiting cell growth, but when mutated it allows cells to grow uncontrollably. The researchers have shown that two existing drugs can halt this growth in human cells. This points to a new approach to treating liver cancer.
‘Today Vienna is one of the top addresses with regard to breast cancer research,’ Professor Michael Gnant proudly reports – and he certainly knows what he is talking about.
Bladder cancer (BC) is the most common malignancy involving the urinary system and the ninth most common malignancy worldwide.
How to cut the high cost of cancer drugs engendered high interest at the recent Forum on Hospital Management held in Vienna.
Patients with locally advanced rectal cancer have been treated with intra-operative radiotherapy (IORT) for over twenty years. Partly due to this type of radiation, survival rates in a group of patients considered to have inoperable cancer changed dramatically from five to 70 percent.
One of the earliest widespread applications of precision medicine in cancer care is helping patients and physicians decide whether chemotherapy is needed, a new study finds.
New policy recommendations on preventing occupational exposure to cytotoxic drugs were launched in the European Parliament on 26 April 2016, an important new initiative designed to protect healthcare professionals working across the EU.
Nanoparticles known as Cornell dots, or C dots, have shown great promise as a therapeutic tool in the detection and treatment of cancer. Now, the ultrasmall particles – developed more than a dozen years ago by Ulrich Wiesner, the Spencer T. Olin Professor of Engineering at Cornell University – have shown they can do something even better: kill cancer cells without attaching a cytotoxic drug.
Melanomas account among the eight most frequent deadly cancers in Europe and Northern America. Two major clinical criteria separate melanomas from most other cancers: the risk to die from a melanoma is a question of being less or more than 1 mm – and not a question of cm. About 95% of patients with melanomas ≤0.5 mm in thickness are clinically cured by early detection and appropriate melanoma…
A team of researchers at Yale found that a treatment using bioadhesive nanoparticles loaded with a potent chemotherapy drug proved more effective and less toxic than conventional treatments for gynecological cancer.
Italian-led research has highlighted the value of utilising additional screening technologies to help diagnose breast cancer in some women. Interim analysis from the Adjunct Screening with Tomosynthesis or Ultrasound in Women with Mammography-Negative Dense Breasts (ASTOUND) study has delivered evidence of the potential benefit of adding either ultrasound or tomosynthesis to standard mammograms…
New research confirms that an innovative procedure combining MRI and ultrasound to create a 3D image of the prostate can more accurately locate suspicious areas and help diagnose whether it’s prostate cancer.
Changes in the genetic make-up of tissue samples can be detected quickly and easily using a new method based on nanotechnology. This report researchers from the Swiss Nanoscience Institute, the University of Basel and the University Hospital Basel in first clinical tests with genetic mutations in patients with malignant melanoma.
A small device implanted under the skin can improve breast cancer survival by catching cancer cells, slowing the development of metastatic tumors in other organs and allowing time to intervene with surgery or other therapies. These findings suggest a path for identifying metastatic cancer early and intervening to improve outcomes.
To treat or not to treat? That is the question researchers at the Department of Energy’s Lawrence Berkeley National Laboratory (Berkeley Lab) hope to answer with a new advance that could help doctors and their cancer patients decide if a particular therapy would be worth pursuing.
NIBIB researchers have created a nanovaccine that could make a current approach to cancer immunotherapy more effective while also reducing side effects. The nanovaccine helps to efficiently deliver a unique DNA sequence to immune cells – a sequence derived from bacterial DNA and used to trigger an immune reaction. The nanovaccine also protects the DNA from being destroyed inside the body, where…
Multidrug resistance (MDR) is the mechanism by which many cancers develop resistance to chemotherapy drugs, resulting in minimal cell death and the expansion of drug-resistant tumors. To address the problem of resistance, researchers at the National Institute of Biomedical Imaging and Bioengineering (NIBIB) at the National Institutes of Health (NIH) have developed nanoparticles that…